

# Kenchi Takenaka

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/3451886/publications.pdf>

Version: 2024-02-01

7  
papers

112  
citations

1478505

6  
h-index

1720034

7  
g-index

8  
all docs

8  
docs citations

8  
times ranked

149  
citing authors

#	ARTICLE	IF	CITATIONS
1	An open-label, randomized controlled trial of sulfamethoxazoleâ€“trimethoprim for Pneumocystis prophylaxis: results of 52-week follow-up. <i>Rheumatology Advances in Practice</i> , 2020, 4, rkaa029.	0.7	7
2	Decrease in MPO-ANCA after administration of benralizumab in eosinophilic granulomatosis with polyangiitis. <i>Allergology International</i> , 2019, 68, 539-540.	3.3	20
3	Two cases of type 2 diabetes mellitus in elderly patients successfully treated with monthly exenatide longâ€“acting release. <i>Clinical Case Reports (discontinued)</i> , 2019, 7, 981-983.	0.5	0
4	Optimal regimens of sulfamethoxazole-trimethoprim for chemoprophylaxis of Pneumocystis pneumonia in patients with systemic rheumatic diseases: results from a non-blinded, randomized controlled trial. <i>Arthritis Research and Therapy</i> , 2017, 19, 7.	3.5	41
5	Successful treatment of refractory aortitis in antineutrophil cytoplasmic antibody-associated vasculitis using tocilizumab. <i>Clinical Rheumatology</i> , 2014, 33, 287-289.	2.2	25
6	A dose-escalation regimen of trimethoprimâ€“sulfamethoxazole is tolerable for prophylaxis against Pneumocystis jiroveci pneumonia in rheumatic diseases. <i>Modern Rheumatology</i> , 2013, 23, 752-758.	1.8	12
7	A dose-escalation regimen of trimethoprimâ€“sulfamethoxazole is tolerable for prophylaxis against Pneumocystis jiroveci pneumonia in rheumatic diseases. <i>Modern Rheumatology</i> , 2013, 23, 752-758.	1.8	6